Edition:
United States

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

247.75USD
17 Jul 2018
Change (% chg)

$2.62 (+1.07%)
Prev Close
$245.13
Open
$245.35
Day's High
$248.36
Day's Low
$244.77
Volume
158,453
Avg. Vol
330,498
52-wk High
$248.36
52-wk Low
$191.53

Chart for

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of... (more)

Overall

Beta: 1.14
Market Cap(Mil.): $66,199.26
Shares Outstanding(Mil.): 267.20
Dividend: 0.75
Yield (%): 1.21

Financials

  BDX.N Industry Sector
P/E (TTM): 332.23 41.57 33.15
EPS (TTM): 0.75 -- --
ROI: 0.92 14.53 13.23
ROE: 1.21 17.68 15.27

U.S. investigates bloodstream infections for link to heparin syringes

SHANGHAI/CHICAGO Health agencies are investigating an outbreak of bloodstream infections in children from four U.S. states that may be linked to heparin and saline syringes made by Becton Dickinson and Co, the agencies told Reuters. The U.S. Centers for Disease Control and Prevention has confirmed 14 cases of bloodstream infections in children caused by the same strain of the Serratia marcescens bacterium, the agency's lead investigator on the outbreak said in a telephone interview.

May 11 2018

U.S. investigates bloodstream infections for link to heparin syringes

* 14 children in 4 states have confirmed bloodstream infections

May 11 2018

BRIEF-Becton Dickinson Reports Q2 Loss Per Share $0.19

* BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTER; RAISES FISCAL 2018 GUIDANCE

May 03 2018

BRIEF-Becton Dickinson Files For Potential Mixed Shelf Offering

* BECTON DICKINSON AND CO FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2HvryvV) Further company coverage:

Apr 26 2018

BRIEF-Becton Dickinson Updates Instructions for Use for Certain BD Vacutainer Blood Collection Tubes

* BECAME AWARE OF CONCERNS ABOUT INACCURATE LEAD TEST RESULTS FROM MAGELLAN DIAGNOSTICS LEADCARE TESTING SYSTEMS

Mar 22 2018

BRIEF-Becton, Dickinson To Divest Remaining Investment In Vyaire Medical

* BD TO DIVEST REMAINING INVESTMENT IN VYAIRE MEDICAL TO FUNDS MANAGED BY APAX PARTNERS

Mar 19 2018

BRIEF-Becton Dickinson Launches Circulating Cell-Free DNA Blood Collection Tube in Western Europe

* BD LAUNCHES CIRCULATING CELL-FREE DNA BLOOD COLLECTION TUBE FOR CANCER AND NON-INVASIVE PRENATAL TESTING APPLICATIONS

Feb 20 2018

BRIEF-Becton Dickinson Files For Offering EUR 300 Mln Add. 0.368% Notes

* BECTON DICKINSON AND CO FILES FOR OFFERING EUR 300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ADDITIONAL 0.368% NOTES DUE 2019 - SEC FILING

Feb 16 2018

BRIEF-Becton Dickinson Says Received Pre-Market Approval From FDA For BD Onclarity HPV Assay

* FDA APPROVES NEW HPV TEST THAT DETECTS AND IDENTIFIES HPV GENOTYPES THAT PUT WOMEN AT HIGH RISK FOR CERVICAL CANCER Source text for Eikon: Further company coverage:

Feb 13 2018

BRIEF-Becton Dickinson Q1 Loss Per Share $0.76

* BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD

Feb 06 2018

Earnings vs. Estimates